RxDoctor Payments Data

Robert Flores, MD

Ophthalmology · Charlotte, NCNPI 1265480149

Payments from drug & device makers

$353in general payments, 2019–2025

Across 7 payments — averaging $50.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$170
  • Johnson & Johnson$107
  • AbbVie$42
  • Otsuka America Pharmaceutical, Inc.$21
  • Welch Allyn$14

What the payments were for

  • Food & beverage$33996%
  • Other$144%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alcon2$170
Johnson & Johnson1$107
AbbVie(2 entities)2$42
Otsuka America Pharmaceutical, Inc.1$21
Welch Allyn1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$353 in reported general payments places this provider in the 20th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina

Medicare billing

Part B allowed, 2024
$289,043
Medicare patients
1,354
Services billed
3,140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost136$79,262
RestasisCyclosporine59$75,568
Latanoprost2,506$31,245
CombiganBrimonidine Tartrate/Timolol60$27,209
Brimonidine Tartrate508$23,402
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat845$15,972
Timolol Maleate897$12,180
Brinzolamide56$12,071
Alphagan PBrimonidine Tartrate25$12,007
Travoprost75$10,718
Cyclosporine28$9,923
RocklatanNetarsudil Mesylat/Latanoprost20$9,881
TafluprostTafluprost/Pf34$8,780
XiidraLifitegrast12$8,055
XalatanLatanoprost16$6,248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$42$194,045280 claims
AlconSimbrinza$170$4,82322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 588 ophthalmology providers in North Carolina.

Other ophthalmology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →